Literature DB >> 12399234

Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein.

Deborah E Sullivan1, Mario U Mondelli, David T Curiel, Viktor Krasnykh, Gallina Mikheeva, Paul Gaglio, Cindy B Morris, Srikanta Dash, Michael A Gerber.   

Abstract

BACKGROUND/AIMS: We developed a single-chain antibody fragment (scFv) to the non-structural 3 protein (NS3) of hepatitis C virus (HCV) and tested its ability to interfere with the HCV replication cycle in infected hepatocytes.
METHODS: The variable regions of the human monoclonal antibody CM3.B6 that recognizes a conformational epitope within the helicase domain of NS3 were introduced into adenoviral vectors for expression in mammalian hepatocytes. Expression and binding properties of the scFv were analyzed by immunological assays. Effects of intracellular expression of the scFv on HCV replication were assessed in primary hepatocytes isolated from explanted livers of patients with chronic HCV infection by reverse transcription-polymerase chain reaction.
RESULTS: Transduction of HepG2 cells by the recombinant adenoviruses resulted in stable, efficient expression of scFv in the cytoplasm that was non-toxic to the cells. The scFv specifically bound to its cognate antigen. Significantly, intracellular expression of scFv resulted in a decrease in HCV genomic RNA in HCV infected hepatocytes.
CONCLUSIONS: These results indicate that specific binding of a scFv to NS3 may inhibit one or more functions of this essential viral protein thus interfering with the HCV replication cycle. Copyright 2002 European Association for the Study of the Liver

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399234     DOI: 10.1016/s0168-8278(02)00270-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  The production and application of single-chain antibody fragments.

Authors:  D Blazek; V Celer
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

Review 2.  Understanding helicases as a means of virus control.

Authors:  D N Frick; A M I Lam
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

3.  Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Authors:  Meital Gal-Tanamy; Romy Zemel; Larissa Bachmatov; Rohit K Jangra; Assaf Shapira; Rodrigo A Villanueva; Minkyung Yi; Stanley M Lemon; Itai Benhar; Ran Tur-Kaspa
Journal:  Antiviral Res       Date:  2010-08-10       Impact factor: 5.970

4.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

5.  Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.

Authors:  Ramesh Prabhu; Nutan Khalap; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

6.  Role of an arbovirus nonstructural protein in cellular pathogenesis and virus release.

Authors:  Randall J Owens; Chang Limn; Polly Roy
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 7.  The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target.

Authors:  David N Frick
Journal:  Curr Issues Mol Biol       Date:  2007-01       Impact factor: 2.081

8.  Significance of monoclonal antibodies against the conserved epitopes within non-structural protein 3 helicase of hepatitis C virus.

Authors:  Yixin Bian; Shuoxian Zhao; Shaomei Zhu; Jinfeng Zeng; Tingting Li; Yongshui Fu; Yuanzhan Wang; Xin Zheng; Ling Zhang; Wenjing Wang; Baocheng Yang; Yuanping Zhou; Jean-Pierre Allain; Chengyao Li
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.